維亮控股(08612.HK)中期純利升170.4%至319.18萬港元
格隆匯 8 月 13日丨維亮控股(08612.HK)公佈,截至2020年6月30日止6個月,公司收入為4333.30萬港元,同比增長77.1%;毛利為1519.09萬港元,同比增長13.9%;期內溢利319.18萬港元,同比增長170.4%,每股盈利0.53港仙。
收入增加乃主要由於總體銷售額增加。總體銷售額增加乃由於工具及零件買賣增加。
倘剔除上市開支,期內溢利由去年同期的約530萬港元減少至約320萬港元。期內溢利減少乃主要由於1)維修及保養工程產生的維修及保養開支增加;2)上市相關開支(包括核數師酬金、董事袍金及合規顧問費在上市後增加);及3)工資及員工成本增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.